Cholesterol ester transfer protein inhibition with torcetrapib leads to an increase in cardiovascular events: an effect that is unlikely to be the result of increases in blood pressure alone

托塞曲匹抑制胆固醇酯转移蛋白会导致心血管事件增加：这种效应不太可能仅仅是血压升高所致。